Q1 sales were DKK 170m (vs DKK107m); operating expenses were DKK154m (vs DKK110m); operating income was DKK16m (vs 173m); the cash position was DKK3,491m similar to the end-FY15 position.
27 May 2016
Continued rapid progress with Daratumumab
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Continued rapid progress with Daratumumab
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
27 May 2016 -
Author:
Armelle Moulin -
Pages:
2
Q1 sales were DKK 170m (vs DKK107m); operating expenses were DKK154m (vs DKK110m); operating income was DKK16m (vs 173m); the cash position was DKK3,491m similar to the end-FY15 position.